找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Handbook of Chronic Myeloid Leukemia; Timothy P Hughes,David M Ross,Junia V Melo Book 2014 Springer International Publishing Switzerland 2

[复制链接]
查看: 45403|回复: 37
发表于 2025-3-21 18:23:40 | 显示全部楼层 |阅读模式
书目名称Handbook of Chronic Myeloid Leukemia
编辑Timothy P Hughes,David M Ross,Junia V Melo
视频video
概述A small practical pocketbook that provides hematologists, oncologists, pathologists and other healthcare providers involved in the diagnosis and treatment of CML with a concise and up-to-date survey o
图书封面Titlebook: Handbook of Chronic Myeloid Leukemia;  Timothy P Hughes,David M Ross,Junia V Melo Book 2014 Springer International Publishing Switzerland 2
描述This concise, clinically focused pocket handbook assembles and synthesizes the latest developments and trends in the diagnosis and treatment of CML and provides an authoritative and convenient summary of the latest progress in TKI trials, the molecular monitoring of CML responses, and the development of new therapies to overcome resistance and improve patient care. Chronic myeloid leukemia (CML) is a rare type of leukemia (1–2 per 100,000 people) but is the most common chronic myeloproliferative neoplasm. CML remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level; CML was the first cancer to be associated with a recurring chromosome abnormality, which generates the Philadelphia (Ph) chromosome and its associated fusion gene BCR-ABL1. The clinical outcome for patients with CML has changed dramatically in the past 15 years and this has been due to the development of tyrosine kinase inhibitors (TKIs), compounds that inhibit the activity of the oncogenic BCR-ABL1 protein. A number of first-, second- and third-generation TKIs are now available for the treatment of CML, although a number of treatment challenges remain, not least the
出版日期Book 2014
关键词BCR-ABL signaling; Hematology; Leukemia; Tyrosine kinase inhibitors; pharmacotherapy
版次1
doihttps://doi.org/10.1007/978-3-319-08350-6
isbn_softcover978-3-319-08349-0
isbn_ebook978-3-319-08350-6
copyrightSpringer International Publishing Switzerland 2014
The information of publication is updating

书目名称Handbook of Chronic Myeloid Leukemia影响因子(影响力)




书目名称Handbook of Chronic Myeloid Leukemia影响因子(影响力)学科排名




书目名称Handbook of Chronic Myeloid Leukemia网络公开度




书目名称Handbook of Chronic Myeloid Leukemia网络公开度学科排名




书目名称Handbook of Chronic Myeloid Leukemia被引频次




书目名称Handbook of Chronic Myeloid Leukemia被引频次学科排名




书目名称Handbook of Chronic Myeloid Leukemia年度引用




书目名称Handbook of Chronic Myeloid Leukemia年度引用学科排名




书目名称Handbook of Chronic Myeloid Leukemia读者反馈




书目名称Handbook of Chronic Myeloid Leukemia读者反馈学科排名




单选投票, 共有 0 人参与投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 23:46:18 | 显示全部楼层
发表于 2025-3-22 01:43:55 | 显示全部楼层
Book 2014d provides an authoritative and convenient summary of the latest progress in TKI trials, the molecular monitoring of CML responses, and the development of new therapies to overcome resistance and improve patient care. Chronic myeloid leukemia (CML) is a rare type of leukemia (1–2 per 100,000 people)
发表于 2025-3-22 06:58:29 | 显示全部楼层
发表于 2025-3-22 09:55:24 | 显示全部楼层
发表于 2025-3-22 15:50:13 | 显示全部楼层
发表于 2025-3-22 17:31:33 | 显示全部楼层
发表于 2025-3-23 01:08:06 | 显示全部楼层
发表于 2025-3-23 02:55:35 | 显示全部楼层
Fiction: A Screenplay-to-Understanding,When a patient presents with suspected chronic myeloid leukemia (CML) appropriate assessments are needed to confirm the diagnosis and stage of disease, and to assign a risk score to that patient.
发表于 2025-3-23 08:51:44 | 显示全部楼层
A Brief Note on Looking Forward,Resistance to tyrosine kinase inhibitors (TKIs) can be defined on the basis of its time of onset. Primary resistance is a failure to achieve a significant therapeutic response, whereas secondary or acquired resistance is the progressive reappearance of the leukemic clone after an initial response to the drug.
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-3 18:42
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表